公开(公告)号：US20170165297A1

公开(公告)日：2017-06-15

申请号：US15441658

申请日：2017-02-24

Applicant: ABBOTT LABORATORIES

Inventor： Suzette Pereira ,  Sean Garvey ,  Neile Edens

IPC: A61K33/30 ,  A61K31/353 ,  A61K36/82 ,  A61K36/48 ,  A61K38/01 ,  A23L33/00 ,  A23L2/66 ,  A23L33/105 ,  A23L33/16 ,  A23L33/175 ,  A23L33/19 ,  A61K9/00 ,  A61K38/39

CPC classification number: A61K33/30 ,  A23L2/66 ,  A23L33/105 ,  A23L33/16 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A23L33/195 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0095 ,  A61K31/353 ,  A61K35/20 ,  A61K36/48 ,  A61K36/82 ,  A61K38/011 ,  A61K38/018 ,  A61K38/39 ,  A61K2300/00

Abstract: Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate (“EGCg”) in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc.

公开(公告)号：US20160022617A1

公开(公告)日：2016-01-28

申请号：US14775972

申请日：2014-03-14

Applicant: ABBOTT LABORATORIES

Inventor： Menghua Luo ,  Suzette Pereira ,  Neile Edens ,  Gerard Davis ,  Susan Gawel ,  Raj Chandran

IPC: A61K31/19 ,  G01N33/68

CPC classification number: A61K31/19 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4704 ,  G01N2333/575 ,  G01N2800/52

Abstract: Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

Abstract translation: 提供了使用生物标志物的胰岛素抵抗生物标志物和相关方法。 生物标志物可以是血液生物标志物，包括C肽，胰岛素样生长因子结合蛋白2（IGFBP-2）和瘦蛋白。 还提供了一种减少长期身体不活动对经历长时间身体不活动的受试者或预期在不久的将来会经历长时间身体不活动的受试者的胰岛素抵抗的影响的方法。

公开(公告)号：US09713598B2

公开(公告)日：2017-07-25

申请号：US14775972

申请日：2014-03-14

Applicant: ABBOTT LABORATORIES

Inventor： Menghua Luo ,  Suzette Pereira ,  Neile Edens ,  Gerard Davis ,  Susan Gawel ,  Raj Chandran

IPC: A61K31/19 ,  G01N33/68

CPC classification number: A61K31/19 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4704 ,  G01N2333/575 ,  G01N2800/52

Abstract: Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

公开(公告)号：US20160038457A1

公开(公告)日：2016-02-11

申请号：US14776972

申请日：2014-03-14

Applicant: ABBOTT LABORATORIES

Inventor： Sean Garvey ,  Suzette Pereira ,  Neile Edens

IPC: A61K31/353 ,  A61K9/00 ,  A23L1/30

CPC classification number: A61K31/353 ,  A23L2/50 ,  A23L33/105 ,  A23V2002/00 ,  A23V2200/316 ,  A61K9/0053 ,  A23V2250/214

Abstract: Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition.

Abstract translation: 提供减少肌肉功能下降和改善受试者肌肉功能的方法。 该方法利用有效量的表没食子儿茶素-3-没食子酸酯（EGCg）来增加肌肉血管内皮生长因子A（VEGF）的水平，降低肌生成抑制素水平或两者，从而降低肌肉功能下降或改善肌肉功能。 EGCg可以作为营养组合物的一部分提供。

公开(公告)号：US09844531B2

公开(公告)日：2017-12-19

申请号：US14776972

申请日：2014-03-14

Applicant: ABBOTT LABORATORIES

Inventor： Sean Garvey ,  Suzette Pereira ,  Neile Edens

IPC: A61K31/353 ,  A23L2/50 ,  A61K9/00 ,  A23L33/105

CPC classification number: A61K31/353 ,  A23L2/50 ,  A23L33/105 ,  A23V2002/00 ,  A23V2200/316 ,  A61K9/0053 ,  A23V2250/214

Abstract: Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition.

公开(公告)号：US09579347B2

公开(公告)日：2017-02-28

申请号：US14433538

申请日：2013-10-04

Applicant: ABBOTT LABORATORIES

Inventor： Suzette Pereira ,  Sean Garvey ,  Neile Edens

IPC: A61K33/30 ,  A23L33/00 ,  A61K31/353 ,  A61K38/01 ,  A61K35/20 ,  A61K36/48 ,  A23L2/66 ,  A61K9/00 ,  A61K36/82 ,  A61K38/39

CPC classification number: A61K33/30 ,  A23L2/66 ,  A23L33/105 ,  A23L33/16 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A23L33/195 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0095 ,  A61K31/353 ,  A61K35/20 ,  A61K36/48 ,  A61K36/82 ,  A61K38/011 ,  A61K38/018 ,  A61K38/39 ,  A61K2300/00

Abstract: Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate (“EGCg”) in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc.

Abstract translation: 本文公开了提高表没食子儿茶素没食子酸酯（“EGCg”）在减轻受试者的骨骼肌损失方面的功效的方法。 向营养组合物中的受试者提供EGCg减少肌肉蛋白质降解，从而减轻受试者的骨骼肌损失。 EGCg与营养组合中的锌的组合增强了EGCg对肌肉损失的缓解作用。 具体地，当组合使用时，含有EGCg和锌的营养组合物需要更少的EGCg以获得在含有EGCg但不含锌的相同营养组合物中发生的相同的减轻效果。

公开(公告)号：US20150265650A1

公开(公告)日：2015-09-24

申请号：US14433538

申请日：2013-10-04

Applicant: ABBOTT LABORATORIES

Inventor： Suzette Pereira ,  Sean Garvey ,  Neile Edens

IPC: A61K33/30 ,  A61K38/01 ,  A61K36/82 ,  A23L2/66 ,  A61K38/39 ,  A61K36/48 ,  A23L1/305 ,  A23L1/30 ,  A61K31/353 ,  A61K9/00

CPC classification number: A61K33/30 ,  A23L2/66 ,  A23L33/105 ,  A23L33/16 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A23L33/195 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0095 ,  A61K31/353 ,  A61K35/20 ,  A61K36/48 ,  A61K36/82 ,  A61K38/011 ,  A61K38/018 ,  A61K38/39 ,  A61K2300/00

Abstract: Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate (“EGCg”) in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc.

Abstract translation: 本文公开了提高表没食子儿茶素没食子酸酯（“EGCg”）在减轻受试者的骨骼肌损失方面的功效的方法。 向营养组合物中的受试者提供EGCg减少肌肉蛋白质降解，从而减轻受试者的骨骼肌损失。 EGCg与营养组合中的锌的组合增强了EGCg对肌肉损失的缓解作用。 具体地，当组合使用时，含有EGCg和锌的营养组合物需要更少的EGCg以获得在含有EGCg但不含锌的相同营养组合物中发生的相同的减轻效果。